Astria Therapeutics, Inc. - ATXS STOCK NEWS

Astria Therapeutics, Inc. (NASDAQ:ATXS) reported Q3 2022 financial results, highlighting a net loss of $12 million and a loss per share of $0.87. The company is on track to release preliminary results from its Phase 1a clinical trial of STAR-0215, targeting hereditary angioedema, by the end of 2022. STAR-0215 shows promise with potential quarterly dosing based on preclinical data. Cash position stood at $116.6 million, sufficient to fund operations until mid-2024. R&D expenses increased to $7.7 million, while total expenses for the quarter were $12.4 million, reflecting ongoing development efforts.

Astria Therapeutics (Nasdaq: ATXS) announced that CEO Jill C. Milne will present a corporate overview of the company and its lead program STAR-0215 at the Jefferies London Healthcare Conference on November 16 at 7:25 AM GMT. STAR-0215 is a monoclonal antibody being developed for the treatment of hereditary angioedema, targeting rare allergic and immunological diseases. Investors can access a live webcast of the presentation here, with an archived replay available for 30 days after the event.

Astria Therapeutics (NASDAQ:ATXS) announced the presentation of preclinical data for STAR-0215, a treatment for hereditary angioedema (HAE), at the 2022 ACAAI Annual Scientific Meeting in Louisville, Kentucky. The e-poster, titled "Modeling and Simulation Predicts Robust HAE Attack Suppression with Every Three Month Dosing of STAR-0215," will be presented by Jou-Ku Chung on November 13, 2022 at 12:05 PM ET. STAR-0215 aims for long-lasting prevention of HAE attacks with dosing every three months. The ongoing Phase 1a clinical trial's preliminary results are expected by year-end.

Astria Therapeutics, Inc. (NASDAQ: ATXS) announced the granting of stock options for 46,500 shares on November 1, 2022, under its 2022 Inducement Stock Incentive Plan. The options, available to new employees, have an exercise price of $10.71, matching the stock's closing price on the grant date. These options will vest over four years, with 25% vesting on the first anniversary of the employee's start date and the remainder vesting monthly. The plan aligns with Nasdaq Listing Rule 5635(c)(4) for employee inducements.

Astria Therapeutics (NASDAQ:ATXS) has announced a virtual R&D Day on September 30, focused on STAR-0215, a monoclonal antibody in clinical development for hereditary angioedema (HAE). Dr. Marc Riedl will present on HAE treatment advancements, followed by Astria's management discussing STAR-0215's development. This event aims to enhance understanding of current treatments and improve patient experiences. An archived replay will be available on their website for 30 days post-event.

Astria Therapeutics (NASDAQ:ATXS) has announced presentations at two upcoming investment conferences. CEO Jill C. Milne will give a corporate overview and discuss the lead program STAR-0215, a treatment for hereditary angioedema, at the H.C. Wainwright Global Investment Conference on September 12. She will also participate in a fireside chat at the Ladenburg Thalmann 2022 Healthcare Conference on September 29. Archived replays of the presentations will be available on the company's website for 30 days following the events.

Astria Therapeutics, Inc. (NASDAQ:ATXS) has granted stock options to purchase 5,500 shares of common stock on September 1, 2022, under its 2022 Inducement Stock Incentive Plan. These options are designed for new employees and have an exercise price of $8.68, equivalent to the closing stock price on the grant date. The options will vest over four years, with 25% vesting after one year and the remainder monthly. This move aligns with Nasdaq Listing Rule 5635(c)(4) for inducement grants.

Astria Therapeutics (NASDAQ: ATXS) announced FDA clearance of its IND application for STAR-0215, a treatment for hereditary angioedema (HAE). The company has initiated a Phase 1a clinical trial involving 24 healthy subjects, with preliminary results expected by year-end 2022. Financial results for Q2 2022 show a net loss of $11.3 million, with R&D expenses increasing to $6.6 million. The company has $102.5 million in cash, sufficient to fund operations through 2023. Astria plans to host a virtual R&D Day on September 30, 2022, to discuss STAR-0215's development.

Astria Therapeutics (NASDAQ: ATXS) has initiated a Phase 1a clinical trial for STAR-0215, aimed at treating hereditary angioedema (HAE). This monoclonal antibody, given quarterly, is designed for long-lasting attack prevention. The trial will assess the safety and pharmacodynamics of STAR-0215 involving 24 healthy subjects across three dosing cohorts. Preliminary results are expected by year-end, with the goal of establishing clinical proof of concept. Successful outcomes could position STAR-0215 as a potential best-in-class treatment for HAE.